AARP Eye Center
Search
Evidence-based clinical decision support systems should be broadly integrated.
Drug companies should continue to be prohibited from promoting drugs for uses not approved by the FDA.
Reimportation and importation of prescription drugs from licensed pharmacies and wholesalers operating in Canada should be permitted with strong safety standards.
The Federal Trade Commission should continue monitoring restraints of trade in the generic drug industry.
Efforts to expedite FDA approval processes should ensure that patient safety remains paramount.
Federal and state policymakers should ensure that practices do not unfairly exclude competition in the prescription drug market.